| Autor: |
O'Boyle KP; Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466, USA. KevinPO@aol.com, Murigeppa A, Jain D, Dauber L, Dutcher JP, Wiernik PH |
| Jazyk: |
angličtina |
| Zdroj: |
Medical oncology (Northwood, London, England) [Med Oncol] 2003; Vol. 20 (4), pp. 379-84. |
| DOI: |
10.1385/MO:20:4:379 |
| Abstrakt: |
A 69-yr-old male with a history of familial hemochromatosis and status after liver transplantation was found to have severe thrombocytopenia (platelet count of 8000/microL). He was also anemic and was diagnosed with acute myeloid leukemia (AML) after a bone marrow biopsy. He was started on gemtuzumab ozogamicin (Mylotarg) and developed hepatic and multiorgan failure consistent with veno-occlusive disease within 2 wk. He did not have a history of hematopoietic stem cell transplantation, which is usually the case in AML patients who develop veno-occlusive disease of the liver after treatment with Mylotarg. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink